Silodyx ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-002820-20-NL (EUCTR) | 03/02/2016 | 21/01/2016 | Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? | Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? - Alpha blockers and Multiple Sclerosis (MS) | Bladder dysfunction in Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10069632;Term: Bladder dysfunction;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.1;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Silodyx | Erasmus MC Dept. Urology | NULL | Not Recruiting | Female: yes Male: no | 30 | Phase 3 | Netherlands |